Cellular and extracellular behavior in the gerbil (Meriones unguiculatus) ventral prostate following different types of castration and the consequences of testosterone replacement.
Mongolian gerbils (Meriones unguiculatus) were grouped into two experimental groups: GEx.01 suffered orchiectomy and after 30 days received doses of testosterone cipionate (T), while GEx.02 received weekly and alternated doses of the anti-androgens cyproterone acetate and flutamide for 30 days, and the animals were then euthanized. Structural evaluation reveals a more intense reduction in epithelial height in GEx.02. Smooth muscle cells (SMC) presented a star-shaped aspect after 30 days of hormonal ablation and basal membrane was shown to be more intensely grooved in GEx.01. In both groups, after hormonal replacement, recovery in epithelial height could be noted and the SMC presented its phenotypes, but an increase in RER was seen, characterizing a modulation from its contractile to secreting phenotype. In conclusion, the prostate presented involution capacity after androgen ablation and the ability to reorganize after hormonal replacement, but events resulting from orchiectomy and subsequent T replacement were shown to be more aggressive to the prostate.
Oliveira
Sérgio Marcelino
SM
Department of Cell Biology, IB/UNICAMP, P.O. Box 190, Campinas 13084-971, SP, Brazil.
Leite Vilamaior
Patricia Simone
PS
Corradi
Lara Silvia
LS
Góes
Rejane Maira
RM
Taboga
Sebastião Roberto
SR
D000135:Acid Phosphatase; D000726:Androgen Antagonists / Q000008:administration & dosage*; D000818:Animals; D003534:Cyproterone; D004195:Disease Models, Animal; D018870:Endoplasmic Reticulum, Rough / Q000648:ultrastructure; D004727:Endothelium / Q000648:ultrastructure; D005485:Flutamide; D005849:Gerbillinae; D007150:Immunohistochemistry; D008297:Male; D046529:Microscopy, Electron, Transmission; D009919:Orchiectomy / Q000379:methods; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism; D013739:Testosterone / Q000008:administration & dosage* / Q000097:blood
D000726:Androgen Antagonists; D011944:Receptors, Androgen; D013739:Testosterone; D005485:Flutamide; D003534:Cyproterone; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases